Finnegan Ip Law Podcast Series

Welcome to Last Month at the Federal Circuit—a look at recent decisions from the U.S. Court of Appeals impacting the intellectual property community. In this podcast, Finnegan partner Kathleen Daley takes a look back at important intellectual property related cases in 2018, including Oil States Energy Services, LLC v. Greene’s Energy Group, LLC and SAS Institute Inc. v. Iancu, and other cases where the Supreme Court is continuing to take interest in the Federal Circuit.

Michael Rubin, Fordham Intellectual Property, Media & Entertainment Law Journal (IPLJ) staff member, sits down with Finnegan partner Jeffrey Berkowitz to discuss experiences encountered in his patent practice which covers nearly 30 years. Mr. Berkowitz discusses his international practice which encompasses assisting clients with developing strategic patent portfolios and also litigating in district courts and the Court of Appeals for the Federal Circuit.

Welcome to the Last Month at the Federal Circuit—a look at recent decisions from the U.S. Court of Appeals for the Federal Circuit impacting the intellectual property community. In this podcast, Finnegan partner Mike Jakes reviews recent developments at the Federal Circuit regarding patent eligibility under Section 101, including the recent Ancora Technologies, Inc. v. HTC America, Inc. case.

Welcome to the Last Month at the Federal Circuit—a look at recent decisions from the U.S. Court of Appeals for the Federal Circuit impacting the intellectual property community. In this podcast, Finnegan partner Dori Hines offers insight into three recently-decided cases—Arista v. Cisco, GoPro v. Countour IP Holdings, and Acceleration Bay v. Electronic Arts—all of which were appeals from the PTAB.all of which were appeals from the PTAB.

The Drug Price Competition and Patent Term Restoration Act of 1984–also known as the Hatch-Waxman Act–amended patent law and drug law to facilitate pharmaceutical development and encourage greater access to generic medicines. Under Hatch-Waxman, the Food and Drug Administration requires new drug applications to be accompanied by certain patent information, which the FDA then lists in its Approved Drug Products with Therapeutic Equivalence Evaluations publication, also known as the Orange Book. This can be a complicated process with significant consequences for improper listings. In this podcast, Finnegan attorneys Shana Cyr, David Weingarten and Ashley Winkler discuss what pharmaceutical companies should know about the complex Orange Book listing process.

Welcome to the Last Month at the Federal Circuit – a look at recent Federal Circuit decisions impacting the intellectual property community. In this podcast, Finnegan partner Amanda Murphy offers insight into a recently decided case that involves patent rights of CRISPR technology and the role that standard of review can play in Federal Circuit proceedings.

Welcome to the Last Month at the Federal Circuit—a look at recent Federal Circuit decisions impacting the intellectual property community. In this podcast, Finnegan partner Mike Flibbert offers insight into two recently decided cases—Click-to-Call Technologies v. Ingenio and GoPro v. Contour IP Holding—and their potential implications for those practicing IP law.

In this podcast, Finnegan partner Mike Jakes discusses recent developments in Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals and NantKwest v. Iancu.

Engineered natural products like lab-grown meat and synthetic milks represent the next step in food science. But striving to make a product identical to one found in nature can raise issues regarding the patentability of that product. In this podcast, Finnegan attorneys Virginia Carron and Jessica Marks discuss the current landscape for obtaining patent protection for engineered natural products.

Software as a Medical Device – also referred to as SaMD – is one of the fastest growing innovations in the medical device industry. As with any technology that experiences rapid adoption, challenges related to IP protection often follow. In this series, we’re taking a closer look at IP considerations that SaMD developers should be aware of. In this podcast, Finnegan attorneys Eric Raciti and Cory Bell explore nuances of IP law that life sciences companies should consider when developing an SaMD.

Software as a Medical Device – also referred to as SaMD – is one of the fastest growing innovations in the medical device industry. As with any technology that experiences rapid adoption, challenges related to intellectual property protection often follow. In this series, we take a close look at IP considerations that SaMD developers should be aware of as they enter this market. In this podcast, Finnegan partners Shana Cyr and Susan Tull explore the interplay between intellectual property and Food and Drug Administration (FDA) submissions for SaMD.

In this podcast, Finnegan partners Beth Ferrill and Trenton Ward offer insight into the recently decided case Sirona Dental Systems v. Institut Straumann AG, and its potential implications for practice before the PTAB.

Software as a Medical Device – also referred to as SaMD – is one of the fastest growing innovations in the medical device industry. As with any technology that experiences rapid adoption, challenges related to intellectual property protection often follow. In this series, we take a close look at IP considerations that SaMD developers should be aware of as they enter this market. In this podcast, Finnegan attorneys Beth Ferrill and Sean Damon will explore the impact of open source on the SaMD industry and considerations for either obtaining a patent or protecting the innovation as a trade secret.

Software as a Medical Device – also referred to as SaMD – is one of the fastest growing innovations in the medical device industry. As with any technology that experiences rapid adoption, challenges related to intellectual property protection often follow. In this series, we take a close look at IP considerations that SaMD developers should be aware of as they enter this market. In this podcast, Finnegan attorneys Susan Tull and Cory Bell explore challenges tech companies may face when developing SaMD.

In May 2018, the U.S. District Court for the District of Massachusetts amended its Patent Proceedings Rule – Local Rule 16.6 – in an effort to streamline and speed up patent litigation. In this podcast, Finnegan partners Alissa Lipton and Christopher Schultz share insights into the Rule changes and how they may impact patent litigation in the district.

Software as a Medical Device–also referred to as SaMD–is one of the fastest growing innovations in the medical device industry. As with any technology that experiences rapid adoption, challenges related to intellectual property protection often follow. In this series, we take a close look at IP considerations that SaMD developers should be aware of as they enter this market. In this podcast, Finnegan attorneys Margaret Esquenet and Beth Ferrill explore IP challenges related to the branding of SaMDs.

In this podcast, Finnegan partner Kathleen Daley offers insight into three recently-decided Federal Circuit cases and their potential implications: WesternGeco v. Ion Geophysical, XY v. Trans Ova Genetics, and PGS Geophysical v. Iancu.

In this podcast, Finnegan partner Mike Jakes offers an update on the the Aatrix Software and Berkheimer cases. He also shares insight into two cases dealing with attorney misconduct.  

In SAS Institute v. Iancu, the Supreme Court addressed the question of “[w]hen the Patent Office initiates an inter partes review, must it resolve all of the claims in the case, or may it choose to limit its review to only some of them?” The Court found that, contrary to the prior USPTO practice, the Board may not limit institution to only some of the challenged claims. Finnegan attorneys Joshua Goldberg, Kevin Rodkey, and Cory Bell join us now to discuss what happens now.

On April 24, 2018, the Supreme Court handed down two opinions in cases related to inter partes review (IPR). In a 7-2 decision, the Court upheld the constitutionality of IPRs in Oil States Energy Services, LLC v. Greene's Energy Group, LLC. Then, in SAS Institute v. Matal, the Court ruled 5-4 that the Patent Trial and Appeal Board must review all challenged IPR claims or none at all. In this podcast, Finnegan attorneys Trenton Ward and Rachel Emsley share their insight into these two very important cases.